21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

24 October 2022 - Event

BIO-EUROPE 2022: FACILITATING GLOBAL PARTNERSHIPS THAT DRIVE LIFE SCIENCE DEALMAKING

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…

BEAM News
Member News
Events

Latest news of BEAM Alliance

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

25 November 2021 - BEAM Alliance

Antimicrobial Resistance Campaign 2021

Antimicrobial Resistance Campaign 2021. The needs of SMEs must be considered when reshaping the regulatory framework in AMR innovation.

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

page 1/5

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

13 September 2022 - ABAC therapeutics

ABAC Therapeutics: Scientists from Spain and India Lead an International Project to Develop New Antibiotics Against Gram-Negative Bacteria

ABAC Therapeutics, together with the artificial intelligence (AI) company, Peptris, and the Foundation for Neglected Disease Research (FNDR), with scientific…

07 September 2022 - Debiopharm International

One Drug for One Bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress

Now is the time to encourage the development of new antibiotic classes by establishing new business models that will assure…

07 September 2022 - Destiny Pharma plc

Destiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening…

31 August 2022 - Omnix Medical

Omnix Medical received NIH grant for the development of its novel antimicrobial peptide OMN6

Omnix Medical is developing a promising pipeline of novel anti-infective agents based on a new approach of fighting infectious diseases,…

11 August 2022 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

04 August 2022 - F2G Ltd

F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim

F2G is a biotech company with operations in the UK, US, and Austria focused on the discovery and development of…

page 1/44

Events

02 November 2022

Antimicrobial Resistance Digital Event

Act now: Incentives & Strategies to drive Innovation in the Antimicrobial Resistance Market.

24 October 2022

BIO-EUROPE 2022: FACILITATING GLOBAL PARTNERSHIPS THAT DRIVE LIFE SCIENCE DEALMAKING

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…

15 October 2022

6th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

11 October 2022

REVIVE Webinar: Drug discovery strategies: Focusing on synthetic compounds and natural products

REVIVE is a space for everybody with an interest in antimicrobial R&D.

30 August 2022

CDC/FDA Public Online Workshop: Drug Development Considerations for the Prevention of HealthCare-Associated Infections

The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are co-sponsoring this public virtual workshop.

23 August 2022

REVIVE Webinar: Challenges of developing antibiotic combinations

REVIVE is a space for everybody with an interest in antimicrobial R&D.

10 August 2022

REVIVE Webinar: Animal models to study the activity of antibiotics

REVIVE is a space for everybody with an interest in antimicrobial R&D.

26 July 2022

REVIVE Webinar: New approaches to antibiotic discovery

REVIVE is a space for everybody with an interest in antimicrobial R&D.

22 June 2022

JPIAMR Innovation Online Workshop: Developing Diagnostic tools for Drug Resistant Infections for Human and Animal Health

JPIAMR, in partnership with Innovate UK KTN, are hosting this innovation workshop to provide information about the challenges in translating…

page 1/14